Key Details
Price
$5.80Annual Revenue
$2.00 MAnnual ROE
-30.61%Beta
2.58Events Calendar
Next earnings date:
Mar 25, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 25, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's unique FASN inhibition mechanism effectively reduces liver fibrosis, positioning it as a superior treatment for advanced MASH compared to competitors like Tirzepatide. SGMT's robust financials, including $188.5 million in liquidity and no debt, provide a solid foundation for advancing Denifanstat through Phase 3 trials.
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024.
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
Dr. Scott Friedman will discuss the unmet need in MASH and present Sagimet's topline data from the FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH.
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced that management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.
Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows promising results in treating nonalcoholic steatohepatitis and acne. The company has a strong safety profile and sufficient cash to last until 2025.
FAQ
- What is the primary business of Sagimet Biosciences - Seri?
- What is the ticker symbol for Sagimet Biosciences - Seri?
- Does Sagimet Biosciences - Seri pay dividends?
- What sector is Sagimet Biosciences - Seri in?
- What industry is Sagimet Biosciences - Seri in?
- What country is Sagimet Biosciences - Seri based in?
- When did Sagimet Biosciences - Seri go public?
- Is Sagimet Biosciences - Seri in the S&P 500?
- Is Sagimet Biosciences - Seri in the NASDAQ 100?
- Is Sagimet Biosciences - Seri in the Dow Jones?
- When was Sagimet Biosciences - Seri's last earnings report?
- When does Sagimet Biosciences - Seri report earnings?
- Should I buy Sagimet Biosciences - Seri stock now?